Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient.
Cancer, cilt.129, ss.2610-2612, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Editöre Mektup
- Cilt numarası: 129
- Basım Tarihi: 2023
- Doi Numarası: 10.1002/cncr.34938
- Dergi Adı: Cancer
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Public Affairs Index, Veterinary Science Database
- Sayfa Sayıları: ss.2610-2612
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic-phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient-based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.